ClinicalTrials.gg
Not yet recruitingNCT07950332Updated Nov 20, 2026

A Phase II Clinical Study of HRS-7172 as Monotherapy or in Combination With Anti-Tumor Therapy in Participants With Advanced Lung Cancer to Evaluate Safety, Tolerability, and Efficacy

A Phase 2 interventional study of HRS-7172 tablet and HRS-7172; SHR-4610 ; chemotherapy in Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 850 studies in Lung Neoplasms with a site in China — 376 open to participants now, 423 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
146th of 590
200 · median 90
Started
2026
with 91 others
Phase 2
152 of 850
74 open now
Primary completion
2028-12
later than 363 of 422 live
Registered
850th of 850
by date

Among the 850 studies in Lung Neoplasms with a site in China, this one is the 146th largest by planned enrollment of the 590 interventional ones that give a count, is one of 92 that started in 2026, is one of 152 in phase 2, reaches primary completion later than 363 of the 422 other live ones, and was the 850th registered.

Lung Neoplasms

5,434 studies on the registry are indexed under Lung Neoplasms; 1,348 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

376 of the 850 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

371 more — sign in →

All 376 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 996 Lung Neoplasms studies recruiting now, 685 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 850 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-7172 combined with other antitumor therapies in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-7172 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.

03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand the study and voluntarily sign the form, with good compliance and willingness to cooperate with follow-up.
  2. Aged 18 to 75 years (inclusive), regardless of gender.
  3. (ECOG) performance status score of 0 or 1.
  4. or cytologically confirmed locally advanced or non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.
  5. Expected survival ≥ 12 weeks.
  6. At least one per 1.1 criteria.
  7. Female participants of must have a negative serum pregnancy test within 7 days prior to the first dose and must not be lactating. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to comply with requirements and refrain from donating oocytes or sperm.

Exclusion criteria

Exclusion Criteria:

  1. Participants with untreated or active central nervous system (CNS) , history of or current , or spinal cord compression.
  2. Other within 5 years prior to first dose of study drug.
  3. Prior systemic anti-tumor therapy (including chemotherapy, targeted therapy, immunotherapy, biologic therapy, or other drugs) within 4 weeks prior to first dose of study drug.
  4. Severe cardiovascular or cerebrovascular diseases.
  5. Gastrointestinal disorders affecting drug administration/absorption.
  6. bleeding symptoms within 3 months (May 2026 to July 2026) prior to first study dose, or obvious hemoptysis within 1 month (July 2026 to July 2026) prior to first study dose.
  7. Clinically uncontrolled third-space effusion, or third-space effusion requiring intervention within 7 days prior to first study treatment.
  8. Severe infection within 4 weeks prior to initiation of study treatment.
  9. History of immunodeficiency, including positive test; active (positive HBsAg at screening with HBV DNA ≥ 1000 copies/mL or 500 IU/mL) or (positive anti-HCV and HCV RNA above the lower limit of detection).
  10. Active pulmonary tuberculosis infection within 1 year prior to enrollment as identified by medical history or imaging, or a history of active pulmonary tuberculosis more than 1 year prior without adequate treatment.
  11. Toxicities from prior anti-tumor therapy (including but not limited to gastrointestinal reactions, skin toxicity) not recovered to ≤ Grade 1 or to the level specified in the eligibility criteria
  12. Major organ surgery within 4 weeks prior to first dose of study drug.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Part A

    partA: HRS-7172 tablet

    Drug: HRS-7172 tablet

  • Experimental
    partB-1

    partB-1:HRS-7172+SHR-4610± chemotherapy

    Drug: HRS-7172; SHR-4610 ; chemotherapy

  • Experimental
    partB-2

    partB-2:HRS-7172+SHR-9839(sc) /SHR-4610

    Drug: HRS-7172 ; SHR-9839(sc) ; SHR-4610

Interventions

  • DrugHRS-7172 tablet

    HRS-7172 tablet fixed dose

  • DrugHRS-7172; SHR-4610 ; chemotherapy

    HRS-7172 fixed dose+ /SHR-4610 fixed dose± chemotherapy fixed dose

  • DrugHRS-7172 ; SHR-9839(sc) ; SHR-4610

    HRS-7172 fixed dose+SHR-9839(sc) fixed dose b/SHR-4610 fixed dose

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v6.0)

    Time frame: 2 month

  2. Determine dose recommendation (RP2D)

    Time frame: 6month

  3. Objective response rate (ORR)

    Time frame: 1 year

Secondary outcomes

  1. Duration of response (DoR)

    Time frame: 1 year

  2. Disease control rate (DCR)

    Time frame: 1 year

  3. Progression free survival (PFS)

    Time frame: Time Frame: 1 year

  4. Overall survival (OS)

    Time frame: 1 year

  5. Blood concentrations of HRS-7172

    Time frame: 12 weeks

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 24 months is below that.

Counting every sponsor, half of 362 studies reached it within 65 months; a quarter within 34 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 30, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950332
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Sida Zhu
Contact
sida.zhu.sz15@hengrui.com
86-18611089618
Jing Cheng
Contact
jing.cheng@hengrui.com
86-19551398612

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion